At its meeting on 17 June 2024, the Transparency Council adopted opinion No. 93/2024 on the On the inclusion in the reimbursement of medicines containing the active substance salbutamolum in terms of indications for use or dosage, or method of administration different from those specified in the Summary of Product Characteristics of the Summary of Product Characteristics, i.e. bradycardia in children under 18 years of age.
Publication on the list of opinions on active substances for off-label indications >>